Contents

Search

vortioxetine (Trintellix)

Brintellix (vortioxetine) and Brilinta (ticagrelor) name confusion. [3] Name changed to Trintellix [4] Indications: - major depression Dosage: - start 10 mg QD - usual dose 20 mg QD - consider 5 mg QD if poorly tolerated Tabs: 5, 10, 15 & 20 mg Adverse effects: - nausea/vomiting - constipation Mechanism of action: - serotonin reuptake inhibition - serotonin receptor 5-HT1A agonist - partial agonist serotonin receptor 5-HT1B - antagonist serotonin receptor 5-HT3A - antagonist serotonin receptor 5-HT7

Interactions

drug adverse effects of antidepressants

General

antidepressant

Database Correlations

PUBCHEM correlations

References

  1. FDA News Release: Sept. 30, 2013 FDA approves new drug to treat major depressive disorder. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm370416.htm
  2. Prescriber's Letter 20(12): 2013 Detail-Document#: 291206 Comparison of Antidepressants (subscription needed) http://www.prescribersletter.com
  3. FDA MedWatch. July 30, 2015 Brintellix (vortioxetine) and Brilinta (ticagrelor): Drug Safety Communication - Name Confusion. https://mail.google.com/mail/u/0/?tab=wm#inbox/14edfa25fc57b461
  4. Brooks M From Brintellix to Trintellix : Drug's Name Changes for Safety. Medscape Medical News. May 2, 2016 http://www.medscape.com/viewarticle/862760